Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
JHI John Hancock Investors Trust
SLGN Silgan Holdings Inc
GBX Greenbrier Companies Inc
GOOG Alphabet Inc
PUCKU Goal Acquisitions Corp
PRGO Perrigo Company PLC
INBS Intelligent Bio Solutions Inc
BLNK Blink Charging Co
PYOIF Promotora y Operadora de Infraestructura SAB de CV
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. Its second product candidate, AGLE-177, is a novel PEGylated ( polyethylene glycol) human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria. The Company is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and Phase I/II open-label extension trial. It is also conducting a Phase I/II clinical trial for the treatment of patients with Homocystinuria.

Closing Price
$0.5001
Day's Change
0.0769 (18.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.54
Day's Low
0.4155
Volume
(Heavy Day)
Volume:
6,313,461

10-day average volume:
2,857,019
6,313,461

Company Profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. Its second product candidate, AGLE-177, is a novel PEGylated ( polyethylene glycol) human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria. The Company is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and Phase I/II open-label extension trial. It is also conducting a Phase I/II clinical trial for the treatment of patients with Homocystinuria.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
4.48x
Price/Book (MRQ)
0.39x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

November 2022
Current Month
1.2M
Previous Month
611.0K
Percent of Float
1.96%
Days to Cover
0.4901 Days

Share Information

AGLE is in a share class of common stock
Float
60.3M
Shares Outstanding
61.5M
Institutions Holding Shares
71
77.03%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Russell J. Cox
  • Jeffrey M. GoldbergPres.
  • Jonathan D. AlspaughCFO
  • Leslie SloanCOO
  • Jim KastenmayerPres.

Address

Insider Trading

During the most recent quarter, 118K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.